Clinical Cancer Research, Vol 3, Issue 4 553-557, Copyright © 1997 by American Association for Cancer Research

ARTICLES

Decreased folylpolyglutamate synthetase activity in tumors resistant to fluorouracil-folinic acid treatment: clinical data

M Chazal, S Cheradame, JL Formento, M Francoual, P Formento, MC Etienne, E Francois, H Richelme, M Mousseau, C Letoublon, D Pezet, H Cure, JF Seitz and G Milano
Hopital Pasteur, Service de Chirurgie Generale, 30 Av de la voie romaine, 06002 Nice Cedex, France.

Thymidylate synthase (TS) is the main target for fluorouracil (FU). Optimal cellular concentrations of reduced folates in polyglutamated forms [via folylpolyglutamate synthetase (FPGS)] are necessary for achieving maximal TS inhibition. The aim of this multicentric prospective study was to analyze the link between clinical response to FU therapy for liver metastases of colorectal carcinoma and tumoral TS and FPGS activities. Forty-four advanced colorectal cancer patients (15 women and 29 men; median age 63, range, 27-78 years) receiving a standard FU-folinic acid protocol were included. A single hepatic tumoral biopsy was obtained systematically at the time of diagnosis. For 24 patients, a biopsy in the primary colon tumor was available. TS and FPGS activities were measured by radioenzymatic assays. Clinical response on hepatic metastases was 1 complete response, 12 partial responses, 14 stabilizations, and 17 progressions. In hepatic biopsies, TS activity (median, 185; range, <10-3111 fmol/min/mg protein) and FPGS activity (median, 1270; range, <400-3730 fmol/min/mg protein) exhibited a wide variability. TS activity in primary tumors (median, 461; range, 35-2565 fmol/min/mg protein) was significantly higher than in hepatic metastases. No difference was observed between primaries and metastases for FPGS. FPGS activity expressed in liver metastases was significantly correlated to that expressed in primaries. The distribution of TS activity in liver metastases was not significantly different between responsive and nonresponsive patients. However, FPGS activity measured in liver metastases was significantly higher in responsive patients (median, 1550 fmol/min/mg protein) than in nonresponsive patients (median, 1100 fmol/min/mg protein). A discriminant analysis revealed that 24 of the 25 patients exhibiting a liver FPGS activity </=1100 fmol/min/mg protein and/or a liver TS >320 fmol/min/mg protein were nonresponding patients. These data establish for the first time the potential importance of tumoral FPGS activity for assessing FU-folinic acid responsiveness in the clinical setting.

This article has been cited by other articles:

				M.-C. Etienne-Grimaldi, J.-L. Formento, M. Francoual, E. Francois, P. Formento, N. Renee, P. Laurent-Puig, M. Chazal, D. Benchimol, J.-R. Delpero, et al. K-Ras Mutations and Treatment Outcome in Colorectal Cancer Patients Receiving Exclusive Fluoropyrimidine Therapy Clin. Cancer Res., August 1, 2008; 14(15): 4830 - 4835. [Abstract] [Full Text] [PDF]

				R. C. Cho, P. D. Cole, K.-J. Sohn, G. Gaisano, R. Croxford, B. A. Kamen, and Y.-I. Kim Effects of folate and folylpolyglutamyl synthase modulation on chemosensitivity of breast cancer cells Mol. Cancer Ther., November 1, 2007; 6(11): 2909 - 2920. [Abstract] [Full Text] [PDF]

				K-J Sohn, F Smirnakis, D N Moskovitz, P Novakovic, Z Yates, M Lucock, R Croxford, and Y-I Kim Effects of folylpolyglutamate synthetase modulation on chemosensitivity of colon cancer cells to 5-fluorouracil and methotrexate Gut, December 1, 2004; 53(12): 1825 - 1831. [Abstract] [Full Text] [PDF]

				E. Odin, Y. Wettergren, S. Nilsson, R. Willen, G. Carlsson, C. P. Spears, L. Larsson, and B. Gustavsson Altered Gene Expression of Folate Enzymes in Adjacent Mucosa Is Associated with Outcome of Colorectal Cancer Patients Clin. Cancer Res., December 1, 2003; 9(16): 6012 - 6019. [Abstract] [Full Text] [PDF]

				M.-C. Etienne, M. Chazal, P. Laurent-Puig, N. Magne, C. Rosty, J.-L. Formento, M. Francoual, P. Formento, N. Renee, E. Chamorey, et al. Prognostic Value of Tumoral Thymidylate Synthase and p53 in Metastatic Colorectal Cancer Patients Receiving Fluorouracil-Based Chemotherapy: Phenotypic and Genotypic Analyses J. Clin. Oncol., June 15, 2002; 20(12): 2832 - 2843. [Abstract] [Full Text] [PDF]

				J. Ciccolini, L. Peillard, A. Evrard, P. Cuq, C. Aubert, A. Pelegrin, P. Formento, G. Milano, and J. Catalin Enhanced Antitumor Activity of 5-Fluorouracil in Combination with 2'-Deoxyinosine in Human Colorectal Cell Lines and Human Colon Tumor Xenografts Clin. Cancer Res., April 1, 2000; 6(4): 1529 - 1535. [Abstract] [Full Text]

				B. van Triest, H. M. Pinedo, Y. van Hensbergen, K. Smid, F. Telleman, P. S. Schoenmakers, C. L. van der Wilt, J. A. M. van Laar, P. Noordhuis, G. Jansen, et al. Thymidylate Synthase Level as the Main Predictive Parameter for Sensitivity to 5-Fluorouracil, but not for Folate-based Thymidylate Synthase Inhibitors, in 13 Nonselected Colon Cancer Cell Lines Clin. Cancer Res., March 1, 1999; 5(3): 643 - 654. [Abstract] [Full Text] [PDF]

				K. J. Chave, I. E. Auger, J. Galivan, and T. J. Ryan Molecular Modeling and Site-directed Mutagenesis Define the Catalytic Motif in Human gamma -Glutamyl Hydrolase J. Biol. Chem., December 15, 2000; 275(51): 40365 - 40370. [Abstract] [Full Text] [PDF]